Related Experiment Video
Updated: Jan 16, 2026

Simultaneous Assessment of Kinship, Division Number, and Phenotype via Flow Cytometry for Hematopoietic Stem and Progenitor Cells
Published on: March 24, 2023
Assessing completeness of cancer family history in EHRs using genetically defined kinships: A cross-sectional study
Daniel Kiser1,2, Gai Elhanan1,2, Karen A Schlauch1,2
1University of Nevada, Reno School of Medicine, Reno, NV.
Purpose:
Family history (FHx) is the most widely available tool for reducing mortality and morbidity caused by heritable diseases. However, FHx may be inadequately documented. Our objective was to assess the rate at which cancers in patient relatives are documented as FHx in electronic health records (EHRs).
Methods:
Our primary analysis included 903 Healthy Nevada Project participants who had cancer-diagnosed patient relatives removed by ≤2 degrees in a kinship analysis. The rate of successful EHR documentation of relatives' cancer type was quantified using generalized estimating equations.
Results:
The population-average rate of cancer FHx documentation in the EHR was 45.2% (95% confidence interval [CI]: 42.0%-48.4%). The odds ratio (OR) for successful documentation was 0.39 (95% CI: 0.24-0.64) for patients >69 years old versus patients <30 years old. Additionally, FHx documentation increased with years since a relative's cancer diagnosis, with an OR of 2.19 (95% CI: 1.57-3.06) for patients with ≥10 years since their relative's diagnosis versus <5 years. Compared with females, males were less likely to document female-specific cancers (OR 0.31 [95% CI: 0.19-0.49]) but more likely to document male-specific cancers (OR 2.42 [95% CI: 1.16-5.04]). In a secondary analysis of 83 patients with variants in BRCA1 or BRCA2, 34 (41%) met familial risk criteria based on their EHRs; however, an additional 6 (7%) would have met criteria if cancers in known relatives had been documented.
Conclusion:
More than half of cancers affecting patient relatives were not documented as FHx in patient EHRs. This suggests that familial risk is underestimated, likely resulting in missed opportunities to reduce cancer mortality and morbidity.
More Related Videos
05:53Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
05:58Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format
Published on: August 20, 2018
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pedigree Analysis
Cancer Prevention
Some...
Behavioral Genetics and Its Designs
The primary methodologies used in behavior genetics include family studies, twin studies, and adoption studies, each providing unique...
Cancer Survival Analysis
Longitudinal Research